Jinom&Company Obtains Patent Rights for Anticancer Immune-Enhancing Substance
[Asia Economy Reporter Junho Hwang] Genome & Company announced on the 29th that it has acquired a patent related to a new target for anticancer and immune-enhancing purposes. A representative of Genome & Company stated, "This invention concerns the anticancer use of substances that inhibit the activation or expression of Contactin-4 (CNTN-4)" and added, "We plan to apply this to the research and development of new drug target-based immune checkpoint inhibitor candidates."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
